Wealthfront Advisers LLC Buys 34,942 Shares of Gilead Sciences, Inc. $GILD

Wealthfront Advisers LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 248,854 shares of the biopharmaceutical company’s stock after purchasing an additional 34,942 shares during the quarter. Wealthfront Advisers LLC’s holdings in Gilead Sciences were worth $27,590,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Southland Equity Partners LLC grew its stake in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares during the period. Twelve Points Wealth Management LLC boosted its holdings in Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after acquiring an additional 98 shares in the last quarter. Argentarii LLC grew its stake in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares during the period. Lodestar Private Asset Management LLC increased its holdings in shares of Gilead Sciences by 3.6% during the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 100 shares in the last quarter. Finally, Advantage Trust Co raised its position in shares of Gilead Sciences by 13.6% during the second quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,500 shares of company stock worth $8,281,540. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Citigroup lifted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a report on Tuesday, August 19th. Wolfe Research boosted their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research report on Friday, July 25th. Finally, UBS Group boosted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Stock Performance

GILD stock opened at $120.94 on Friday. The business has a 50 day moving average of $115.47 and a 200-day moving average of $111.07. The firm has a market cap of $150.06 billion, a PE ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The business’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.